Financial News
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
14,112 articles
Intrusion Stock Tanks 8% as Q4 Earnings Miss, Revenues Decline Y/Y
INTZ Q4 2025 loss narrows y/y but revenue falls on delayed U.S. government contract funding, while Shield and public safety initiatives drive future...
📰
3 Weaknesses to Weigh Before You Buy Palantir (PLTR) Stock
This high-growth tech stock has some glaring flaws.
Chip Shortage 2026: Why CPUs From Intel And AMD Are Getting Harder To Find
The semiconductor sector is facing renewed pressure as supply shortages intensify and external risks weigh on sentiment.
CPU Shortage Adds To...
Chip Shortage 2026: Why CPUs From Intel And AMD Are Getting Harder To Find
The semiconductor sector is facing renewed pressure as supply shortages intensify and external risks weigh on sentiment.
CPU Shortage Adds To...
Chip Shortage 2026: Why CPUs From Intel And AMD Are Getting Harder To Find
The semiconductor sector is facing renewed pressure as supply shortages intensify and external risks weigh on sentiment.
CPU Shortage Adds To...
Chip Shortage 2026: Why CPUs From Intel And AMD Are Getting Harder To Find
The semiconductor sector is facing renewed pressure as supply shortages intensify and external risks weigh on sentiment.
CPU Shortage Adds To...
Chip Shortage 2026: Why CPUs From Intel And AMD Are Getting Harder To Find
The semiconductor sector is facing renewed pressure as supply shortages intensify and external risks weigh on sentiment.
CPU Shortage Adds To...
Chip Shortage 2026: Why CPUs From Intel And AMD Are Getting Harder To Find
The semiconductor sector is facing renewed pressure as supply shortages intensify and external risks weigh on sentiment.
CPU Shortage Adds To...
Chip Shortage 2026: Why CPUs From Intel And AMD Are Getting Harder To Find
The semiconductor sector is facing renewed pressure as supply shortages intensify and external risks weigh on sentiment.
CPU Shortage Adds To...
Chip Shortage 2026: Why CPUs From Intel And AMD Are Getting Harder To Find
The semiconductor sector is facing renewed pressure as supply shortages intensify and external risks weigh on sentiment.
CPU Shortage Adds To...
Chip Shortage 2026: Why CPUs From Intel And AMD Are Getting Harder To Find
The semiconductor sector is facing renewed pressure as supply shortages intensify and external risks weigh on sentiment.
CPU Shortage Adds To...
Chip Shortage 2026: Why CPUs From Intel And AMD Are Getting Harder To Find
The semiconductor sector is facing renewed pressure as supply shortages intensify and external risks weigh on sentiment.
CPU Shortage Adds To...
Chip Shortage 2026: Why CPUs From Intel And AMD Are Getting Harder To Find
The semiconductor sector is facing renewed pressure as supply shortages intensify and external risks weigh on sentiment.
CPU Shortage Adds To...
Jim Cramer: Bitcoin, Gold 'Failed' As Crisis Hedges—All He Saw Were Margin Calls
CNBC’s Jim Cramer on Wednesday said neither Bitcoin (CRYPTO: BTC) nor gold functioned as crisis hedges during the U.S.-Iran war, arguing he...
Jim Cramer: Bitcoin, Gold 'Failed' As Crisis Hedges—All He Saw Were Margin Calls
CNBC’s Jim Cramer on Wednesday said neither Bitcoin (CRYPTO: BTC) nor gold functioned as crisis hedges during the U.S.-Iran war, arguing he...
📰
Can Pinterest Reach $27? 3 Things Must Go Right After Morgan Stanley’s Target Cut
Pinterest (NYSE:PINS) has had a brutal stretch. Shares are down nearly 30% year-to-date and more than 46% over the past year, sitting at $18.66 after...
MDA Space stock has suffered a harsh reversal: is it a buy now?
The MDA Space stock price slumped by 10% on Tuesday, moving from a low of $28.40, its lowest level since March 5. It has dropped by 13% from its...
The Trade Desk stock price has imploded: will it plunge to $15?
The Trade Desk stock price remains in a freefall and is hovering near its lowest level since April 202o. It has become one of the worst-performing...
Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback
Anavex Life Sciences Corp. (NASDAQ:AVXL) shares are tumbling on Wednesday after the company announced it has withdrawn its application for marketing...
UK says Chinese wind turbine maker poses national security threat
Ming Yang’s plans to build Scottish factory thwarted
Middle East faces at least $25B repair bill for damaged energy infra
The cost to repair and restore damaged energy infrastructure in the Middle East could climb to at least $25 billion, according to initial estimates...
Pentagon Wants to Shift Funds to Interceptors as Iran War Drags
The Pentagon wants to shift roughly $1.5 billion in previously approved funding to buy critical missile interceptors from Lockheed Martin Corp. and...
KB Home Q1 Earnings Meet Estimates, Revenues Miss, Both Down Y/Y
KBH's Q1 earnings meet estimates, but revenues miss, both falling Y/Y as weaker demand and lower orders prompt a cut to the full-year delivery...
KB Home Q1 Earnings Meet Estimates, Revenues Miss, Both Down Y/Y
KBH's Q1 earnings meet estimates, but revenues miss, both falling Y/Y as weaker demand and lower orders prompt a cut to the full-year delivery...
KB Home Q1 Earnings Meet Estimates, Revenues Miss, Both Down Y/Y
KBH's Q1 earnings meet estimates, but revenues miss, both falling Y/Y as weaker demand and lower orders prompt a cut to the full-year delivery...
KB Home Q1 Earnings Meet Estimates, Revenues Miss, Both Down Y/Y
KBH's Q1 earnings meet estimates, but revenues miss, both falling Y/Y as weaker demand and lower orders prompt a cut to the full-year delivery...
NYC Faces Possible Strike by 34,000 Doormen, Building Workers
New York City apartment residents are being put on notice of a potential strike by building staff as soon as next month as the union representing the...
📰
Micron Falls as Q2 Earnings and AI Compression Put Memory Stocks on Edge
Micron Technology (NASDAQ:MU) shares retreated as much as 5% in early Wednesday trading, extending a brutal week that had already seen the stock fall...
📰
Kuehn Law Encourages Investors of Five9, Inc. to Contact Law Firm
NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and...
FIVN Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Five9, Inc. - FIVN
NEW YORK, March 25, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of...
Trade Desk Stock Stalls As Investors Weigh Publicis Fallout And AI Risks
Trade Desk Inc (NASDAQ:TTD) shares are trading flat Wednesday morning as investors continue to digest a mix of company-specific pressure and broader...
📰
This athleisure giant is primed for a sharp move lower. How to trade it using options
Tony Zhang walks CNBC Pro readers through this put vertical.
📰
JLL CEO says growth is now uncertain in the Middle East
JLL has a major footprint in the Middle East, managing and leasing properties in Dubai and Abu Dhabi in the United Arab Emirates and in Riyadh, Saudi...
Will The U.S. Hit A Recession? Moody’s Warns Of ‘Real Threat’ Amid Iran War
Some economists cautioned the U.S. economy would be able to absorb the shock of the Iran war.
📰
Molson Coors Could Drop Another 3% as Barclays Slashes Target to $40 With Underweight Rating
Molson Coors (NYSE:TAP) has been under sustained pressure heading into 2026. Shares are down nearly 2.00%% over the past week, and more than 13% year...
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data
Karyopharm Therapeutics stock sinks 18% after mixed phase III data show spleen benefit but no symptom edge for selinexor combo in myelofibrosis,...
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data
Karyopharm Therapeutics stock sinks 18% after mixed phase III data show spleen benefit but no symptom edge for selinexor combo in myelofibrosis,...
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data
Karyopharm Therapeutics stock sinks 18% after mixed phase III data show spleen benefit but no symptom edge for selinexor combo in myelofibrosis,...